Table 1.  Susceptibilities of Achromobacter xylosoxidans^a

Antibiotic

n

Range

MIC₅₀

MIC₉₀

Breakpoint^b

% Susceptible

Reference

Amikacin

Amikacin

33

50

8-128

16->128

128

>128

128

>128

<16

≤16

13

76

Gentamicin

33

4-64

64

64

<4

13

Gentamicin

16

256

256

256

<4

0

5

Gentamicin

Gentamicin                                                

15

50

1-64

4->128

>64

64

>64

>128

<4

≤4

20

76

Kanamycin

16

64-512

128

256

<16

0

5

Netilmicin

33

8-64

64

64

<8

13

Netilmicin

16

64-256

128

256

<8

0

5

Tobramycin

33

16-64

32

64

<4

0

13

Amidinocillin

33

32->256

256

>256

13

Ampicillin

Ampicillin

33

50

16->128

4->128

32

32

>128

128

<8

≤8

0

13

76

Amoxycillin

16

32-512

64

256

<8

0

5

Amoxycillin clavulanate

16

16-64

32

64

<8/4

0

5

Amoxycillin clavulanate

33

4->128

16

64

<8/4

13

Piperacillin

33

0.5->128

0.5

64

<16

13

Piperacillin

16

0.5-8

4

8

<16

100

5

Piperacillin

Piperacillin

Piperacillin tazobactam

15

50

50

<2->256

0.06-4

0.06-2

<2

0.5

0.5

256

2

1

<16

≤16

≤16/2

20

76

76

Temocillin

33

64->256

>256

>256

13

Ticarcillin

15

<2->256

4

>256

<16

20

Ticarcillin

16

4-512

16

128

<16

5

Ticarcillin clavulanate

16

2-16

4

8

<16/2

100

5

Ticarcillin clavulanate

33

0.25-64

1

32

<16/2

13

Ticarcillin clavulanate

15

<2-128

<2

128

<16/2

20

Cefamandole

33

4-128

16

32

<8

13

Cefazolin

33

16-128

128

128

<8

0

13

Ceforanide

33

4-256

256

256

13

Cefotaxime

33

8-64

32

64

<8

13

Cefotaxime

16

64-256

256

256

<8

0

5

Cefotaxime

15

16->64

64

>64

<8

0

20

Cefotetan

33

16-256

128

256

<16

13

Cefoxitin

16

256

256

256

<8

0

5

Ceftazidime

33

1-64

4

16

<8

13

Ceftazidime

Ceftazidime

15

50

2->64

1-32

8

4

16

16

<8

≤8

20

76

Ceftriaxone

Cefoperazone

Cefoperazone sulbactam

Cefepime

33

50

50

50

2-128

2-8

1-4

8-128

32

2

2

32

64

4

4

128

<8

≤16

≤16/8

<8

13

76

76

76

Cefuroxime

33

32-128

64

64

<8

0

13

Cephalothin

16

128-256

128

256

<8

0

5

Aztreonam

16

32-64

64

64

<8

0

5

Aztreonam

Aztreonam

15

50

32->64

64-128

64

64

>64

128

<8

≤8

0

20

76

Imipenem

33

0.25-4

0.5

2

<4

100

13

Imipenem

Imipenem

15

50

1->16

0.5-4

2

2

8

4

<4

≤4

20

76

Meropenem

Meropenem

15

50

0.25-4

0.25-4

1

1

4

2

≤4

20

76

Ciprofloxacin

33

1-64

4

16

<1

13

Ciprofloxacin

16

2-8

4

8

<1

0

5

Ciprofloxacin

Ciprofloxacin

15

50

1->8

1->128

32

2

64

16

<1

≤1

20

76

Norfloxacin

Norfloxacin

33

50

8-64

8->128

32

16

64

64

≤4

13

76

Ofloxacin

33

1-64

4

32

<2

13

Pefloxacin

33

1-64

4

32

13

Pipemidic acid

16

512

512

512

5

Nalidixic acid

Colistin

Chloramphenicol

Erythromycin

Rifampicin

Minocycline

16

50

50

50

50

50

128

1-64

8->128

8->128

8-64

2-64

128

4

32

64

16

4

128

32

128

>128

32

8

≤2

≤8

≤1

≤4

≤4

5

76

76

76

76

76

Trimethoprim-

sulphamethoxazole^c

Trimethoprim-

sulphamethoxazole^c

33

50

0.12-64

0.06-64

0.2

1

12

32

<2/38

≤2/38

13

76

Table 2.  Susceptibilities of cloxacillin-sensitive ß-lactamase-producing Achromobacter xylosoxidans^a

Antibiotic

n

Range

MIC₅₀

MIC₉₀

Breakpoint^b

% Susceptible

Amoxicillin

41

4-64

8

64

<8

Amoxicillin clavulanate ^c

41

2-32

4

8

<8/4

Azlocillin

41

<0.12-2

0.25

0.5

Piperacillin

41

<0.12-1

0.5

0.5

<16

100

Piperacillin tazobactam^d

41

<0.12-1

0.5

0.5

<16/4

100

Ticarcillin

41

0.25-8

1

4

<16

100

Ticarcillin clavulanate ^c

41

0.25-2

1

1

<16/2

100

Cefamandole

41

4-64

16

32

<8

Cefoperazone

41

0.5-4

2

4

<16

100

Cefoperazone clavulanate ^c

41

<0.12-4

2

2

<16

100

Cefotaxime

41

16-128

64

64

<8

0

Cefotaxime clavulanate ^c

41

16-64

64

64

<8

0

Cefoxitin

41

64->256

256

256

<8

0

Ceftazidime

41

1-16

4

8

<8

Ceftazidime clavulanate ^c

41

1-16

4

8

<8

Cefuroxime

41

>256

>256

>256

<8

0

Cefuroxime clavulanate ^c

41

>256

>256

>256

<8

0

Moxalactam

41

0.25-8

2

4

<8

100

Imipenem

41

1-4

2

2

<4

100

Table 3.  Susceptibilities of cloxacillin/clavulanic acid-susceptible ß-lactamase-producing Achromobacter  xylosoxidans ^a

Antibiotic

n

Range

MIC₅₀

MIC₉₀

Breakpoint^b

% Susceptible

Amoxicillin

17

>256

>256

>256

<8

0

Amoxicillin clavulanate ^c

17

<2-128

64

128

<8/4

Azlocillin

17

4-64

32

64

Piperacillin

17

4-128

32

64

<16

Piperacillin tazobactam^d

17

0.5-16

1

4

<16/4

100

Ticarcillin

17

64->256

>256

>256

<16

0

Ticarcillin clavulanate ^c

17

0.5-64

16

64

<16/2

Cefamandole

17

16-256

32

128

<8

Cefoperazone

17

16-128

64

128

<16

Cefoperazone clavulanate ^c

17

1-8

2

8

<16

100

Cefotaxime

17

64->256

64

>256

<8

0

Cefotaxime clavulanate ^c

17

32->256

256

>256

<8

0

Cefoxitin

17

128->256

256

>256

<8

0

Ceftazidime

17

2-32

16

32

<8

Ceftazidine clavulanate ^c

17

2-16

4

8

<8

Cefuroxime

17

>256

>256

>256

<8

0

Cefuroxime clavulanate ^c

17

>256

>256

>256

<8

0

Moxalactam

17

0.5-8

2

2

<8

100

Imipenem

17

1-2

2

2

<4

100

Antibiotic

Range

MIC₅₀

MIC₉₀

Breakpoint^a

% Susceptible

Table 5.  In vitro susceptibilities of Achromobacter xylosoxidans subsp. denitifricans^a

Antibiotic

n

Range

MIC₅₀

MIC₉₀

Breakpoint^b

% Susceptible

Amoxycillin

10

0.5-512

32

128

<8

Amoxycillin clavulanate ^c

10

0.5-128

16

32

<8/4

Piperacillin

10

0.125-1024

1

4

<16

Ticarcillin

10

0.125-256

8

64

<16

Ticarcillin clavulanate ^c

10

0.125-256

2

4

<16/2

Cefotaxime

10

0.125-256

2

4

<16/2

Cefoxitin

10

0.125-256

128

256

<8

Cephalothin

10

0.125-128

32

128

<8

Aztreonam

10

32-64

32

64

<8

0

Ciprofloxacin

10

0.125-8

2

8

<1

Pipemidic acid

10

8-512

256

512

Nalidixic acid

10

2-128

128

256

Gentamicin

10

0.125-256

128

256

<4

Kanamycin

10

0.125-512

128

256

<16

Netilmicin

10

0.125-256

128

256

<8

Table 6.  In vitro susceptibilities of Achromobacter  piechaudii^a

Antibiotic

n

Range

MIC₅₀

MIC₉₀

Breakpoint^b

% Susceptible

Amoxycillin

5

4-64

16

32

<8

Amoxycillin clavulanate ^c

5

1-2

2

2

<8/4

100

Piperacillin

5

0.5-1

0.5

1

<16

100

Ticarcillin

5

8-32

8

16

<16

100

Ticarcillin clavulanate ^c

5

1-4

2

2

<16/2

100

Cefotaxime

5

64

64

64

<8

0

Cefoxitin

5

64

64

64

<8

0

Cephalothin

5

8-16

8

16

<8

Aztreonam

5

16

16

16

<8

0

Ciprofloxacin

5

2-8

2

4

<8

0

Pipemidic acid

5

256

256

256

Nalidixic acid

5

2-32

4

8

Gentamicin

5

16-128

32

64

<4

0

Kanamycin

5

8-32

8

8

<16

Netilmicin

5

2-32

4

8

<8

Table 7.  In vitro susceptibilities of Alcaligenes faecalis

Antibiotic

Ampicillin

N

18

Range

2->128

MIC₅₀

8

MIC₉₀

>128

Breakpoint^a

<8                             

        Reference

                    76

Amoxycillin

34

2-1024

16

64

<8

6

Amoxycillin clavulanate ^b

34

0.5-128

2

4

<8/4

6

Piperacillin

Piperacillin

Piperacillin tazobactam

34

18

18

1-256

0.5-512

0.25-256

4

1

0.5

16

64

32

<16

<16

<16/2

6

76

76

Ticarcillin

34

1-512

16

64

<16

6

Ticarcillin clavulanate ^b

34

0.5-32

2

8

<16/2

6 

Cefotaxime

34

0.5-128

2

8

<8

6

Cefoxitin

34

2-128

4

8

<8

6

Cephalothin

Cefoperazone

Cefoperazone sulbactam

Ceftazidime

Cefepime

34

18

18

18

18

2-128

1-32

0.5-2

1-32

4-64

8

1

0.5

4

8

32

8

2

8

16

<8

<16

<16/8

<8

<8

6

76

76

76

76 

Aztreonam

34

32

32

32

<8

6

Ciprofloxacin

34

0.5-8

2

4

<1

6 

Pipemidic acid

34

8-512

256

256

6 

Nalidixic acid

34

128

128

128

6 

Gentamicin

34

32-512

32

64

<4

6 

Kanamycin

34

4-512

128

256

<16

6 

Netilmicin

34

1-256

8

16

<8

6